Japanese  
  Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Combination Overcomes Breast Cancer Resistance… >
Combination Overcomes Breast Cancer Resistance to Herceptin

Published: March 14, 2011.
By University of Texas M. D. Anderson Cancer Center
http://www.mdanderson.org

HOUSTON - Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.

Adding the drug saracatinib to Herceptin treatment shrinks previously resistant tumors by cutting off at least five different molecular pathways, each of which can resist, said senior author Dihua Yu, M.D., Ph.D., professor in MD Anderson's Department of Molecular and Cellular Oncology.

"Scientists have identified so many ways by which a tumor resists Herceptin that it raises an important issue for treatment," Yu said. "Will we have to give patients six drugs or 10 drugs to block them all? The side effects would be awful. Two pills are better. This combination is a promising therapy for those with Herceptin-resistant breast cancer."

Working in cell lines, mouse models of breast cancer and checking their work in human tumor samples, Yu and colleagues identified SRC, a known cancer-promoting protein, as the crucial common downstream component of multiple resistance pathways.

Saracatinib is an SRC inhibitor, thwarting that protein and allowing Herceptin to work again in tumors that have a high amount of the HER2 protein.

Only about 26 percent of women with HER2-positive breast cancer respond to Herceptin as single therapy. Between 40 and 60 percent respond to the drug when combined with other chemotherapy.

Combination is ready for clinical trials

Yu said saracatinib has been tested in phase I and phase II clinical trials as a single treatment against late-stage cancers. It has a favorable side effects profile.

"It didn't work as a single agent, but very few drugs work by themselves against late stage disease," Yu said. "Our experiments confirmed its lack of efficacy as a sole treatment. But combined with Herceptin, it's beautiful."

Another SRC inhibitor, dasatinib, has been approved by the U.S. Food and Drug Administration as an anti-cancer drug, but it has harsher side effects, said Siyuan Zhang, Ph.D., a postdoctoral fellow in Yu's lab and the paper's first author.

A tumor-suppressor's job

In 2004, Yu's lab discovered that loss of the tumor-suppressing gene known as PTEN led to Herceptin-resistant tumors. PTEN is a phosphotase - a protein whose function is to strip phosphate chemical groups off of other molecules.

PTEN has two components, one to remove phosphate groups from lipids, and another to remove them from proteins. PTEN's target protein however, was unknown.

Zhang discovered that SRC is a PTEN target. With its phosphate groups, SRC is active. PTEN stifles SRC by peeling away the phosphates.

If PTEN loss leads to Herceptin resistance, and PTEN targets SRC, would that make SRC the culprit?

On the trail of SRC

In a series of experiments the researchers found:

  • SRC is active in breast cancer cells once vulnerable but now resistant to Herceptin and in cells that are resistant from the start.
  • Activation of SRC drives resistance to Herceptin. Tumors with low SRC levels treated by Herceptin shrunk to 20 percent of their original volume in 21 days while SRC-heavy tumors increased by nearly 400 percent over the same time in mouse experiments.
  • SRC activity correlates with patient response to Herceptin. Assessing SRC activation in samples of 57 human breast cancer tumors, the team found that more than 90 percent of tumors with low SRC responded compared with 40 percent of tumors with active SRC.
  • Patients with little active SRC had a median survival of 57.9 months compared with 34.2 months in those with high SRC activity.
  • SRC is activated by a number of receptor tyrosine kinases that cause resistance, including IGF-1R, EGFR, ERBB2, HER3, and Met, separate pathways that work through SRC. "Block SRC, and you reverse them all," Zhang said.


Crushing resistance

Combining Herceptin and saracatinib to treat resistant tumors in mice reduced tumor volume by 90 percent in 25 days. Herceptin alone kept tumor volume about the same during the same period, while control and saracatinib alone permitted growth of more than 200 percent.

The difference was more striking in tumors deficient in SRC's enemy, the PTEN tumor-suppressor. The combination reduced tumor volume by more than 90 percent while the two drugs alone allowed growth of between 200 and 400 percent.

This study was funded by grants from the National Cancer Institute, MD Anderson Breast Specialized Program of Research Excellence; Department of Defense Center of Excellence; Susan G. Komen Breast Cancer Foundation Promise Grant; the Cancer Prevention and Research Institute of Texas, the MD Anderson Breast SPORE Career Development Award and Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
This is form to send feedback to the editors. Tell us what you think about this article. All comments are not published. If you are looking for a response to a question please use our another feedback page.
Related »

Cancer 
12/8/11 
Exemestane Plus Everolimus Increased Progression-free Survival
By American Association for Cancer Research
Everolimus in combination with exemestane has shown promise for the treatment of breast cancer. …
Breast 
11/14/11 
Signaling Pathway Linked to Inflammatory Breast Cancer May Drive Disease Metastasis
By American Association for Cancer Research
Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients …
Statins 
12/6/12 
★ 
UT MD Anderson Study Finds Link Between Statins And Improved Survival in Inflammatory Breast Cancer
By University of Texas M. D. Anderson Cancer Center
HOUSTON - Researchers from The University of Texas MD Anderson Cancer Center found statins, the commonly used drug to lower cholesterol, improved progression-free survival in patients with inflammatory breast …
Chemotherapy 
3/4/14 
Imprint of Chemotherapy Linked to Inflammation in Breast Cancer Survivors
By Emory Health Sciences
Many breast cancer survivors experience fatigue and other debilitating symptoms that persist months to years after their course of treatment has ended. …
Dasatinib 
12/12/13 
New Drug Combination Delayed Disease Progression for Subgroup of Women with Metastatic Breast Cancer
By American Association for Cancer Research
SAN ANTONIO — Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according …
Hortobagyi 
5/31/14 
★ 
Women with Metastatic Breast Cancer Can Safely Receive Bisphosphonates Less Frequently, Without Comp
By University of Texas M. D. Anderson Cancer Center
CHICAGO – Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first …
Cancer 
7/1/11 
Worse Outcomes for Older Breast Cancer Patients with Other Health Problems
By Journal of the National Cancer Institute
Older breast cancer patients with certain other health problems have higher mortality rates than patients without these problems according to a study published online June 30 in the Journal …
Cancer 
11/14/12 
★★★★ 
Cancer: Exercise Reduces Tiredness
By Wiley
Aerobic exercise can help relieve the fatigue often associated with cancer and cancer treatment, according to Cochrane researchers. Their updated systematic review strengthens findings from an earlier version on …
Therapy 
4/1/12 
★ 
PI3K/MTOR Pathway Proteins Tied to Poor Prognosis in Breast Cancer
By University of Texas M. D. Anderson Cancer Center
CHICAGO - Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported …
Denosumab 
12/10/10 
Denosumab Delayed Time to First Skeletal-related Side Effect
By American Association for Cancer Research
SAN ANTONIO — For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented …
More » 
 
ScienceNewsline  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition
The selection and placement of stories are determined automatically by a computer program. All contents are copyright of their owners except U.S. Government works. U.S. Government works are assumed to be in the public domain unless otherwise noted. Everything else copyright ScienceNewsline.